Andrew King becomes President of R&D at Jade Biosciences (NASDAQ: JBIO)

Rhea-AI Filing Summary

Jade Biosciences, Inc. reported that its Board of Directors appointed Andrew King, BVMS, Ph.D. as the company’s President, Research & Development, effective April 18, 2026. Dr. King previously served as Chief Scientific Officer and Head of Research & Development, and his compensation was unchanged with this new role.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Board of Directors, President, Research & Development, Chief Scientific Officer, Emerging growth company

4 terms

Board of Directors financial

"On April 18, 2026, the Board of Directors of Jade Biosciences, Inc."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

President, Research & Development financial

"appointed Andrew King, BVMS, Ph.D. as the Company’s President, Research & Development"

Chief Scientific Officer financial

"Dr. King was previously the Company’s Chief Scientific Officer and Head of Research & Development."

Emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

NASDAQ false 0001798749 0001798749 2026-04-18 2026-04-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 18, 2026

Jade Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-40544		83-1377888
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

221 Crescent St., Building 23
Suite 105
Waltham, MA		02453
(Address of principal executive offices)		(Zip Code)

(Registrant’s telephone number, including area code): (781) 312-3013

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		JBIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 18, 2026, the Board of Directors of Jade Biosciences, Inc. (the “Company”) appointed Andrew King, BVMS, Ph.D. as the Company’s President, Research & Development, effective as of April 18, 2026. Dr. King was previously the Company’s Chief Scientific Officer and Head of Research & Development. No changes were made to Dr. King’s compensation in connection with such appointment.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Jade Biosciences, Inc.
Date: April 22, 2026				By:		/s/ Bradford Dahms
				Name:		Bradford Dahms
				Title:		Chief Financial Officer

FAQ

What executive change did Jade Biosciences (JBIO) announce on April 18, 2026?

Jade Biosciences appointed Andrew King, BVMS, Ph.D. as President, Research & Development, effective April 18, 2026. He previously served as the company’s Chief Scientific Officer and Head of Research & Development, so this represents an internal promotion within the existing leadership team.

What was Andrew King’s prior role at Jade Biosciences (JBIO)?

Before becoming President, Research & Development, Andrew King, BVMS, Ph.D. was Jade Biosciences’ Chief Scientific Officer and Head of Research & Development. The appointment keeps him focused on the company’s research pipeline while giving him a broader leadership title over R&D activities.

When does Andrew King’s new role at Jade Biosciences (JBIO) become effective?

Andrew King’s appointment as President, Research & Development at Jade Biosciences is effective as of April 18, 2026. This effective date matches the day the Board of Directors formally approved the change, making it immediately relevant to the company’s ongoing R&D leadership.

Did Jade Biosciences (JBIO) change Andrew King’s compensation with this appointment?

No, Jade Biosciences made no changes to Andrew King’s compensation in connection with his appointment as President, Research & Development. The filing states explicitly that his pay remains the same even though his leadership title and responsibilities over R&D have been updated.

Who signed the Jade Biosciences (JBIO) report announcing this management change?

The report was signed on behalf of Jade Biosciences by Bradford Dahms, the company’s Chief Financial Officer. His signature confirms the company’s authorization of the disclosure regarding Andrew King’s appointment as President, Research & Development effective April 18, 2026.

Where is Jade Biosciences (JBIO) headquartered according to this filing?

Jade Biosciences lists its principal executive offices at 221 Crescent St., Building 23, Suite 105, Waltham, Massachusetts 02453. This address, along with the company’s telephone number, identifies its main business location and contact point in the United States.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 19.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.9 KB